Skip to main content

BioCryst Pharmaceuticals Value Stock - Dividend - Research Selection

BioCryst Pharmaceuticals

ISIN: US09058V1035, WKN: 896047

Market price date: 04.06.2021
Market price: 16,29 USD




BioCryst Pharmaceuticals Fundamental data and company key figures of the share

Annual reports in USD
Key figures 05-03-2021
Cash flow
Net operating cash flow -137.216.000
Capital Expenditures -514.000
Free cash flow -137.730.000
Balance sheet
Total Equity -19.262.000
Liabilities & Shareholders equity 334.715.000
Income statement
Net income -182.814.000
Eps (diluted) -1,090
Diluted shares outstanding 154.200.000
Net sales/revenue 17.812.000

Fundamental ratios calculated on: 04-06-2021

Ratios
Key figures 04-06-2021
Cash flow
P/C -18,32
   
P/FC -18,24
Balance sheet
ROI-54,62
ROE-5,76
Income statement
P/E-14,95
Div. Yield0,00%
P/B-130,49
P/S141,02


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolBCRX
Market Capitalization2.513.459.968,00 USD
Country
IndicesNASDAQ Comp.
Sectors
Raw Data SourceUS GAAP in Millionen USD
Stock Split
Internetwww.biocryst.com


Description of the company

BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. BioCryst designs, optimizes and develops drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on therapeutic areas. Peramivir is its product, which is a neuraminidase inhibitor for the treatment of patients with influenza. The Company has two purine nucleoside phosphorylase (PNP) inhibitors that are in development, BCX4208 for the treatment of gout and forodesine for the treatment of hematological malignancies. The Company´s pre-clinical compounds include BCX4161, an oral prophylactic drug for hereditary angioedema, and BCX5191, an adenine nucleoside analog targeting viral ribonucleic acid (RNA) polymerase for the treatment of hepatitis C.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.biocryst.com